certify that this correspondence is being deposited with the US Postal Service with sufficient postage as Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Date: August 19, 2003 PATENT Docket No. GC527-C1 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Application of Group Art Unit: 1644 Estell et al. Examiner: Saunders, David Serial No.: 09/500,135 Filed: February 8, 2000 For: Proteins Producing an Altered Immunogenic Response and Methods of Making and Using the Same Supplemental Information Disclosure Statement Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56. This Information Disclosure Statement: (a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a). (b) is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491. (c) as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits. (d) 🛛 is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far

,	rejection either the specifion Depos Inform	on or a notice of allowance, whichever occurs first, and is accompanied by the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as led in 37 CFR §1.97(e), as checked below. Authorization to charge it Account No. 07-1048 in the amount of \$180.00 to cover the cost of this lation Disclosure Statement is provided in the Transmittal Letter submitted the in duplicate.
	Transr No. 07 as spe consi c	is filed after the mailing date of either a final rejection or a notice of nce, whichever occurred first, and is accompanied by authorization (in the nittal Letter submitted herewith in duplicate) to charge Deposit Account -1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification cified in 37 CFR §1.97(e), as checked below. This document is to be dered as a petition requesting consideration of the Supplemental nation Disclosure Statement.
If either of bo	oxes (d) or (e) is checked above, the following "certification" under 37 CFR
§1.97(e) may	need to	be completed.] The undersigned certifies that:
	counte	Each item of information contained in the Information Disclosure nent was cited in a communication mailed from a foreign patent office in a rpart foreign application not more than three months prior to the filing of ormation Disclosure Statement.
	foreigr reason	No item of information contained in this Information Disclosure Statement and in a communication mailed from a foreign patent office in a counterpart application or, to the knowledge of the undersigned after making able inquiry, was known to any individual designated in 37 CFR §1.56(c) than three months prior to the filing of this Information Disclosure ment.
A copy of the i	items 0	n Form PTO-1449 is supplied: PCT Written Opinion for
		ed January 22, 2001 with attached patents and publications.
		one 🗵 only those listed below:
WO 95/05849		
A concise exp	lanatior	of relevance of the items listed on PTO-1449 is:
	\boxtimes	not given
		given for each listed item
		given for only non-English language listed item(s)
	foreigr	in the form of an English language copy of a Search Report from a patent office, issued in a counterpart application, which refers to the portions of the references.

Serial No. 09/50**O**, **1**35 Page 3

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: August 19, 2003

Kamrin T. MácKnight Registration No. 38,230

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-5838 Fax: 650 845-6504

INFORMATION DISCLOSURE CITATION		
Attorney Docket No.: GC527-CAPE	Serial No.: 09/500,135	
Applicant: Estell et al.		
Filing Date: February 8, 2000	Group: 1644	
Page _ 1 _ of _ 1	Date of this Submission: August 19, 2003	
US PA	TENT DOCUMENTS	

Examiner's	Document				Sub-	Filing
Initial	Number	Date	Name	Class	Class	Date
· · · · · · · · · · · · · · · · · · ·						

FOREIGN PATENT DOCUMENTS

Examiner's	Document				Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No
	WO 95/05849	3/2/95	PCT			
	WO 99/06061	2/11/99	PCT			

OTHER DOCUMENTS				
Examiner's				
Initials	Author, Title, Date, Pertinent Pages, etc.			
	Copy of Written Opinion for PCT/US01/02204			
~~				
	Data Considered			
Examiner	Date Considered			
Examiner: In	itial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation			